Acumen Pharmaceuticals
ABOS
80 hedge funds and large institutions have $176M invested in Acumen Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 11 closing their positions.
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
19% more funds holding
Funds holding: 67 → 80 (+13)
19% more capital invested
Capital invested by funds: $148M → $176M (+$27.9M)
5.76% more ownership
Funds ownership: 66.42% → 72.18% (+5.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
63% less call options, than puts
Call options by funds: $1.54M | Put options by funds: $4.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.87M |
| 2 |
Millennium Management
New York
|
+$4.28M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.14M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$778K |
| 5 |
Goldman Sachs
New York
|
+$766K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$882K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$658K |
| 3 |
D.E. Shaw & Co
New York
|
-$530K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$406K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$388K |
ABOS Hedge Fund Activity: Q1 2024 in Review
80 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q1 2024, worth a combined $176M — up 19% from $148M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ABOS positions and 11 closed out — a net gain of 13 holders — while 22 added to existing stakes and 24 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $7.87M. The largest seller was Susquehanna International Group, cutting an estimated $882K.
- 80 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q1 2024, up from 67 in Q4 2023.
- Funds reported $176M of Acumen Pharmaceuticals stock for Q1 2024, up 19% quarter-over-quarter.
- 24 funds opened new Acumen Pharmaceuticals positions in Q1 2024 and 11 closed out, a net change of +13 holders.
- The largest Acumen Pharmaceuticals buyer in Q1 2024 was Fidelity Investments, an estimated $7.87M added.
- The largest Acumen Pharmaceuticals seller in Q1 2024 was Susquehanna International Group, an estimated $882K sold.
Based on aggregated 13F filings for Q1 2024.